Salem Radio Network News Monday, August 15, 2022

Health

Lundbeck, Otsuka announce positive phase III results for Alzheimer’s agitation drug

COPENHAGEN (Reuters) – Danish drugmaker Lundbeck and Japan’s Otsuka Pharmaceutical on Monday announced positive Phase III results for its brexpiprazole drug used to treat agitation in patients with Alzheimer’s-type dementia.

The two companies are planning a regulatory filing to the U.S. Food and Drug Administration later in 2022, Lundbeck said in a statement.

(Reporting by Stine Jacobsen, editing by Terje Solsvik)

Previous
Next

Editorial Cartoons

View More »

Bob Gorrell
Thu, Aug 11, 2022

X CLOSE